Jeena Sikho Lifecare Reports Stellar FY26 Performance

₹222.18 crore net profit; ₹801.35 crore revenue; ₹4.50 dividend declared.

Reader Takeaway: Strong profit growth and international expansion drive investor value, while regulatory costs pose a watch point.

What just happened

Jeena Sikho Lifecare Limited announced its financial results for the fiscal year ended March 31, 2026. The company reported a significant 177.9% year-on-year increase in profit after tax, reaching ₹222.18 crore. Revenue from operations grew by 70.8% to ₹801.35 crore.

Additionally, the Board of Directors recommended a final dividend of ₹4.50 per equity share. The company also disclosed the acquisition of a 51% stake in Back to Roots Ayurveda, UAE, for approximately ₹42.12 crore, with 25% paid upfront.

Why this matters

The robust financial performance indicates strong business expansion and improved profitability. The dividend payout signals confidence in future earnings and a commitment to shareholder returns. The international acquisition marks a significant step in global expansion, potentially opening new revenue streams.

The backstory

In the previous fiscal year (FY25), Jeena Sikho Lifecare reported a net profit of ₹79.94 crore on revenue of ₹469.07 crore. The Earnings Per Share (EPS) for FY26 rose to ₹17.87 from ₹6.43 in FY25.

What changes now

With the acquisition of the UAE entity, Jeena Sikho Lifecare will now consolidate its financials for the first time, reflecting a larger operational scale. The dividend recommendation is subject to shareholder approval at the upcoming Annual General Meeting.

Risks to watch

The company has recognized an incremental financial impact of ₹1.25 crore due to the implementation of new Labour Codes effective November 21, 2025, which could affect future operating costs. The UAE acquisition is also subject to pending regulatory formalities.

Peer comparison

While specific peer comparisons are not provided in the filing, the company's strong growth rates in revenue and profit may position it favorably against other players in the healthcare and Ayurveda sectors, provided the growth is sustainable.

Context metrics (time-bound)

• Revenue: ₹801.35 crore (FY2026) vs ₹469.07 crore (FY2025) - up 70.8%
• Profit After Tax: ₹222.18 crore (FY2026) vs ₹79.94 crore (FY2025) - up 177.9%
• EPS: ₹17.87 (FY2026) vs ₹6.43 (FY2025)
• Dividend: ₹4.50 per share recommended for FY2026.
• UAE Acquisition Cost: ₹42.12 crore for 51% stake.

What to track next

Investors will be keen to monitor the successful completion of regulatory formalities for the UAE acquisition. Additionally, the impact of the new Labour Codes on operational costs and the company's strategy for integrating the international business will be crucial.